Silence Therapeutics (SLN) Return on Sales: 2021-2025
Historic Return on Sales for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to 131.81%.
- Silence Therapeutics' Return on Sales fell 10808.00% to 131.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.50%, marking a year-over-year increase of 204.00%. This contributed to the annual value of 1.05% for FY2024, which is 67.00% up from last year.
- Silence Therapeutics' Return on Sales amounted to 131.81% in Q3 2025, which was down 7.94% from 122.12% recorded in Q2 2025.
- Silence Therapeutics' Return on Sales' 5-year high stood at 0.49% during Q4 2024, with a 5-year trough of 200.92% in Q1 2025.
- Over the past 3 years, Silence Therapeutics' median Return on Sales value was 7.13% (recorded in 2023), while the average stood at 46.94%.
- As far as peak fluctuations go, Silence Therapeutics' Return on Sales surged by 762bps in 2024, and later tumbled by 20,077bps in 2025.
- MRQ analysis of 5 years shows Silence Therapeutics' Return on Sales stood at 3.29% in 2021, then rose by 4bps to 3.16% in 2022, then crashed by 126bps to 7.13% in 2023, then soared by 107bps to 0.49% in 2024, then tumbled by 27,213bps to 131.81% in 2025.
- Its Return on Sales was 131.81% in Q3 2025, compared to 122.12% in Q2 2025 and 200.92% in Q1 2025.